Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | XBP1 | P17861 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23618678 | 0.86 | SYK (0.45) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL31668760 | 0.85 | ALDH1A1 (0.56) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL23618785 | 0.84 | GSK3A (0.44) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL23625487 | 0.83 | SYK (0.48) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL31612079 | 0.83 | SYK (0.49) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL23620493 | 0.83 | SYK (0.46) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL30479295 | 0.83 | SYK (0.46) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL31465472 | 0.82 | IRAK4 (0.32) | NFKB1JUNNFKB2RELAHTT | |
| SCHEMBL24852041 | 0.81 | SYK (0.49) | SYKALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL24851197 | 0.79 | SYK (0.48) | SYKALDH1A1KDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025049253-A1 | BRIDGED CYCLE‑BASED INHIBITORS OF DNA‑DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | DTYMK, DCK, PHKG1 | SYK 2584/4885ALDH1A1 2749/4885KDM4E 997/4885 |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | POLQ, POLK, POLG | SYK 1542/4885ALDH1A1 4034/4885KDM4E 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.